195 related articles for article (PubMed ID: 36780608)
1. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ
J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608
[TBL] [Abstract][Full Text] [Related]
2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
3. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 May; ():JCO2301636. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D; Tawbi H; Lipson EJ; Stephen Hodi F; Rutkowski P; Gogas H; Lao CD; Grob JJ; Moshyk A; Lord-Bessen J; Hamilton M; Guo S; Shi L; Keidel S; Long GV
Eur J Cancer; 2023 Jul; 187():164-173. PubMed ID: 37167764
[TBL] [Abstract][Full Text] [Related]
7. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
8. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Zhao Y; Hu Z; Bathena SP; Keidel S; Miller-Moslin K; Statkevich P; Bello A; Roy A; Suryawanshi S
Clin Cancer Res; 2024 Jan; ():. PubMed ID: 38295151
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab and relatlimab for the treatment of melanoma.
Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
[TBL] [Abstract][Full Text] [Related]
11. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
[TBL] [Abstract][Full Text] [Related]
12. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
Raschi E; Comito F; Massari F; Gelsomino F
Immunotherapy; 2023 Feb; 15(2):85-91. PubMed ID: 36628573
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H; Rutkowski P
Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
16. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
[TBL] [Abstract][Full Text] [Related]
17. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA
Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]